trending Market Intelligence /marketintelligence/en/news-insights/trending/Oq5Io6WadKoQNnKNExCgYQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

First in Human: Opioid epidemic spurs renewed research into drug misuse vaccines

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


First in Human: Opioid epidemic spurs renewed research into drug misuse vaccines

This is a recurring column on clinical research in the early stages of development, what is referred to as phase 1. These are treatments that are being used for the first time in a small number of human patients to determine safety, dosing and general pharmacological activity.

SNL Image

Amid the opioid crisis, an epidemic that kills more than 130 Americans every day, researchers are seeking a vaccine that could render a patient immune to the addictive properties of the potent painkillers.

The National Institutes of Health solicited proposals for the clinical development of vaccines that could prevent the passage of opioids into the brain in a March 2019 broad agency announcement.

According to Roosevelt University assistant professor of medicinal chemistry Margaret Olson, an opioid vaccine would provide another tool in "the arsenal we have to fight against the opioid crisis." Opioid drugs include the illegal drug heroin as well as prescription medicines like oxycodone and morphine.

Vaccines for addiction are developed first by characterizing the chemical structure of the drug, and then linking a chemical piece within the structure called the hapten to an immunogenic carrier protein, which stimulates immune response. When injected into the body, the immune system recognizes the drug as foreign, and the body makes antibodies that will find the drug and prevent it from reaching the brain.

"These types of vaccines would really help individuals not fall down the same addiction spiral again," Olson said.

The vaccines would likely require boosters or revaccinations over the course of weeks or months, Olson added.

SNL Image

Olson who has previously worked with the "pioneer" of vaccines for drugs of abuse, The Scripps Research Institute's Kim Janda said opioid vaccine trials differ only slightly from those held for more typical vaccines against infectious agents, like flu and tetanus.

"You would very much want a patient who has this interest in quitting and breaking their addiction; you want to work together," Olson said. Individuals could potentially take a large dose of drugs and overcome the vaccine if they still wanted to achieve the high associated with opioids.

Cessation Therapeutics is developing an opioid vaccine licensed from Scripps' Janda. The company's research and development director Paul Bremer confirmed the fairly typical makeup for the therapy's trial.

Though vaccines targeting addictive drugs date back to the 1970s, the failure of cocaine vaccines in clinical trials may have scared researchers off for a time, Olson said.

Cocaine vaccines were furthest in development, and some, like Columbia University's Ronald Crystal, are still plugging away in the space. But the opioid crisis has spurred laboratories in another direction, Olson said.

"That has pushed many of the players in the cocaine vaccine field toward opioids just because it's a bigger problem to answer," Olson said.

Trials underway

The NIH has granted the Walter Reed Army Institute of Research resources to push its experimental heroin vaccine through phase 1/2a clinical trials, as well as to begin developing a fentanyl vaccine, the WRAIR said in an October 2018 release.

The vaccine, also licensed to Narcan-maker Opiant Pharmaceuticals Inc., could potentially be used with other approved opioid use disorder medications, such as Indivior PLC's Suboxone, or buprenorphine, Opiant said.

The heroin vaccine will first undergo safety testing, and phase 1 trial testing efficacy is slated for fall 2020.

The New York State Psychiatric Institute's Research Foundation for Mental Hygiene also received grants from the NIH in August 2019 for its bivalent opioid vaccine, which would target both oxycodone and heroin.

The researchers will study the oxycodone and heroin vaccines separately in phase 1a/1b studies for safety and preliminary efficacy, before developing the bivalent vaccine candidate. The studies will recruit individuals diagnosed with opioid use disorder, the project abstract said.

Academics take charge

Not lost on researchers such as Olson and Janda is the absence of large pharmaceutical companies — particularly those who market opioid drugs — investing in opioid vaccines. The researchers noted the absence in a December 2017 article published in EMBO Reports.

The vaccine would need to generate a certain amount of revenue to make the investment worth it, Olson told S&P Global Market Intelligence.

"It's very cold, I don't like it at all, but these companies work based off of a cost-benefit analysis," Olson explained. "Substance use disorder affects [individuals'] operating ability in normal society — whether they can hold a job for long periods of time, whether they have financial means … It's a unique situation that we don't commonly see in the drug development field."